Cargando…

A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain

The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The recognition of an inactive conformation of Abl, in which a catalytically important Asp-Phe-Gly (DFG) motif is flipped by approximately 180° with respect to the active conformation, underlies the specifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Levinson, Nicholas M, Kuchment, Olga, Shen, Kui, Young, Matthew A, Koldobskiy, Michael, Karplus, Martin, Cole, Philip A, Kuriyan, John
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1450098/
https://www.ncbi.nlm.nih.gov/pubmed/16640460
http://dx.doi.org/10.1371/journal.pbio.0040144
_version_ 1782127380615135232
author Levinson, Nicholas M
Kuchment, Olga
Shen, Kui
Young, Matthew A
Koldobskiy, Michael
Karplus, Martin
Cole, Philip A
Kuriyan, John
author_facet Levinson, Nicholas M
Kuchment, Olga
Shen, Kui
Young, Matthew A
Koldobskiy, Michael
Karplus, Martin
Cole, Philip A
Kuriyan, John
author_sort Levinson, Nicholas M
collection PubMed
description The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The recognition of an inactive conformation of Abl, in which a catalytically important Asp-Phe-Gly (DFG) motif is flipped by approximately 180° with respect to the active conformation, underlies the specificity of the cancer drug imatinib, which is used to treat CML. The DFG motif is not flipped in crystal structures of inactive forms of the closely related Src kinases, and imatinib does not inhibit c-Src. We present a structure of the kinase domain of Abl, determined in complex with an ATP–peptide conjugate, in which the protein adopts an inactive conformation that resembles closely that of the Src kinases. An interesting aspect of the Src-like inactive structure, suggested by molecular dynamics simulations and additional crystal structures, is the presence of features that might facilitate the flip of the DFG motif by providing room for the phenylalanine to move and by coordinating the aspartate side chain as it leaves the active site. One class of mutations in BCR–Abl that confers resistance to imatinib appears more likely to destabilize the inactive Src-like conformation than the active or imatinib-bound conformations. Our results suggest that interconversion between distinctly different inactive conformations is a characteristic feature of the Abl kinase domain.
format Text
id pubmed-1450098
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-14500982006-05-16 A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain Levinson, Nicholas M Kuchment, Olga Shen, Kui Young, Matthew A Koldobskiy, Michael Karplus, Martin Cole, Philip A Kuriyan, John PLoS Biol Research Article The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The recognition of an inactive conformation of Abl, in which a catalytically important Asp-Phe-Gly (DFG) motif is flipped by approximately 180° with respect to the active conformation, underlies the specificity of the cancer drug imatinib, which is used to treat CML. The DFG motif is not flipped in crystal structures of inactive forms of the closely related Src kinases, and imatinib does not inhibit c-Src. We present a structure of the kinase domain of Abl, determined in complex with an ATP–peptide conjugate, in which the protein adopts an inactive conformation that resembles closely that of the Src kinases. An interesting aspect of the Src-like inactive structure, suggested by molecular dynamics simulations and additional crystal structures, is the presence of features that might facilitate the flip of the DFG motif by providing room for the phenylalanine to move and by coordinating the aspartate side chain as it leaves the active site. One class of mutations in BCR–Abl that confers resistance to imatinib appears more likely to destabilize the inactive Src-like conformation than the active or imatinib-bound conformations. Our results suggest that interconversion between distinctly different inactive conformations is a characteristic feature of the Abl kinase domain. Public Library of Science 2006-05 2006-05-02 /pmc/articles/PMC1450098/ /pubmed/16640460 http://dx.doi.org/10.1371/journal.pbio.0040144 Text en Copyright: © 2006 Levinson et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Levinson, Nicholas M
Kuchment, Olga
Shen, Kui
Young, Matthew A
Koldobskiy, Michael
Karplus, Martin
Cole, Philip A
Kuriyan, John
A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
title A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
title_full A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
title_fullStr A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
title_full_unstemmed A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
title_short A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
title_sort src-like inactive conformation in the abl tyrosine kinase domain
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1450098/
https://www.ncbi.nlm.nih.gov/pubmed/16640460
http://dx.doi.org/10.1371/journal.pbio.0040144
work_keys_str_mv AT levinsonnicholasm asrclikeinactiveconformationintheabltyrosinekinasedomain
AT kuchmentolga asrclikeinactiveconformationintheabltyrosinekinasedomain
AT shenkui asrclikeinactiveconformationintheabltyrosinekinasedomain
AT youngmatthewa asrclikeinactiveconformationintheabltyrosinekinasedomain
AT koldobskiymichael asrclikeinactiveconformationintheabltyrosinekinasedomain
AT karplusmartin asrclikeinactiveconformationintheabltyrosinekinasedomain
AT colephilipa asrclikeinactiveconformationintheabltyrosinekinasedomain
AT kuriyanjohn asrclikeinactiveconformationintheabltyrosinekinasedomain
AT levinsonnicholasm srclikeinactiveconformationintheabltyrosinekinasedomain
AT kuchmentolga srclikeinactiveconformationintheabltyrosinekinasedomain
AT shenkui srclikeinactiveconformationintheabltyrosinekinasedomain
AT youngmatthewa srclikeinactiveconformationintheabltyrosinekinasedomain
AT koldobskiymichael srclikeinactiveconformationintheabltyrosinekinasedomain
AT karplusmartin srclikeinactiveconformationintheabltyrosinekinasedomain
AT colephilipa srclikeinactiveconformationintheabltyrosinekinasedomain
AT kuriyanjohn srclikeinactiveconformationintheabltyrosinekinasedomain